Published in Lancet Neurol on December 01, 2009
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. J Biol Chem (2011) 2.99
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic study. Neurology (2014) 2.15
100 years of Lewy pathology. Nat Rev Neurol (2012) 2.15
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease. Neurology (2012) 1.69
Parkinson's disease and parkinsonism: neuropathology. Cold Spring Harb Perspect Med (2012) 1.41
A pivotal role for PINK1 and autophagy in mitochondrial quality control: implications for Parkinson disease. Hum Mol Genet (2010) 1.41
CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One (2010) 1.34
α-Synuclein in cutaneous autonomic nerves. Neurology (2013) 1.32
Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurol (2013) 1.26
Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Neuropathology (2015) 1.21
Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain (2011) 1.18
Update on the pathology of dystonia. Neurobiol Dis (2011) 1.18
The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord (2014) 1.17
Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol (2014) 1.14
Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol (2013) 1.11
Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord (2012) 1.11
The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. Brain Pathol (2014) 1.11
Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther (2014) 1.09
Diagnosis and treatment of common forms of tremor. Semin Neurol (2011) 1.08
(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ (2012) 1.07
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol (2015) 1.02
Thinking laterally about neurodegenerative proteinopathies. J Clin Invest (2013) 0.99
Abnormal serine phosphorylation of insulin receptor substrate 1 is associated with tau pathology in Alzheimer's disease and tauopathies. Acta Neuropathol (2014) 0.97
Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci (2013) 0.97
Late-stage Parkinson disease. Nat Rev Neurol (2012) 0.97
When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients. Neurology (2015) 0.96
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis (2011) 0.95
The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Front Behav Neurosci (2012) 0.93
Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron (2014) 0.93
Mitochondrial dysfunction in Parkinson's disease. Parkinsons Dis (2011) 0.93
Disentangling the relationship between lewy bodies and nigral neuronal loss in Parkinson's disease. J Parkinsons Dis (2011) 0.93
Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. J Parkinsons Dis (2015) 0.93
Locus coeruleus neuron density and parkinsonism in older adults without Parkinson's disease. Mov Disord (2012) 0.92
Can we clinically diagnose dementia with Lewy bodies yet? Transl Neurodegener (2013) 0.92
Parkinson's disease--the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J Parkinsons Dis (2013) 0.91
α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol (2013) 0.91
Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation. Neurogastroenterol Motil (2012) 0.90
Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers. J Neuropathol Exp Neurol (2014) 0.89
The pathology roadmap in Parkinson disease. Prion (2013) 0.88
Parkinson disease and incidental Lewy body disease: Just a question of time? Neurology (2015) 0.87
The diagnostic discrimination of cutaneous α-synuclein deposition in Parkinson disease. Neurology (2016) 0.87
DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Mov Disord (2013) 0.86
Alzheimer's disease: pathological mechanisms and recent insights. Curr Neuropharmacol (2011) 0.86
Use of [18F]FDOPA-PET for in vivo evaluation of dopaminergic dysfunction in unilaterally 6-OHDA-lesioned rats. EJNMMI Res (2011) 0.86
Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease. BMC Neurol (2011) 0.86
Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol (2010) 0.86
Clinico-pathological correlations of the most common neurodegenerative dementias. Front Neurol (2012) 0.86
Longitudinal changes in cognition in Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord (2011) 0.85
RTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway. J Neurosci (2014) 0.85
Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease. PLoS One (2013) 0.85
Gene expression in the Parkinson's disease brain. Brain Res Bull (2011) 0.85
Dystrophic serotonin axons in postmortem brains from young autism patients. Anat Rec (Hoboken) (2011) 0.84
Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenone. Neuroscience (2011) 0.84
Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine. Int J Mol Sci (2016) 0.84
Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease. Am J Neurodegener Dis (2012) 0.83
Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies. J Neurochem (2011) 0.83
Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Mol Neurodegener (2011) 0.83
ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun (2013) 0.83
Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases. J Comp Neurol (2013) 0.83
Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease. J Neurol Neurosurg Psychiatry (2016) 0.82
Nerve cells immunoreactive for p62 in select hypothalamic and brainstem nuclei of controls and Parkinson's disease cases. J Neural Transm (Vienna) (2010) 0.82
Visual hallucinations in the differential diagnosis of parkinsonism. J Neurol Neurosurg Psychiatry (2012) 0.82
New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease. Brain Res (2013) 0.81
Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. Acta Neuropathol (2015) 0.81
Sequence variants in eukaryotic translation initiation factor 4-gamma (eIF4G1) are associated with Lewy body dementia. Acta Neuropathol (2012) 0.81
Individual differences in approach-avoidance aptitude: some clues from research on Parkinson's disease. Front Syst Neurosci (2015) 0.81
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology (2017) 0.81
The Concept of Prodromal Parkinson's Disease. J Parkinsons Dis (2015) 0.81
Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment. Cell Mol Neurobiol (2011) 0.80
A new approach to disease-modifying drug trials in Parkinson's disease. J Clin Invest (2013) 0.80
A prognostic view on the application of individualized genomics in Parkinson's disease. Curr Genet Med Rep (2013) 0.80
First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation. Parkinsonism Relat Disord (2011) 0.79
Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease. PLoS One (2016) 0.79
Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. Ann Clin Transl Neurol (2016) 0.79
Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease. Acta Neuropathol Commun (2017) 0.79
Neuropathologic changes associated with atrial fibrillation in a population-based autopsy cohort. J Gerontol A Biol Sci Med Sci (2013) 0.78
Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations. Am J Neurodegener Dis (2013) 0.78
Microstructural changes in the substantia nigra of asymptomatic agricultural workers. Neurotoxicol Teratol (2013) 0.78
Inter-hemispheric asymmetry of nigrostriatal dopaminergic lesion: a possible compensatory mechanism in Parkinson's disease. Front Syst Neurosci (2011) 0.78
Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. FEBS Lett (2015) 0.78
Quantitative assessment of non-motor fluctuations in Parkinson's disease using the Non-Motor Symptoms Scale (NMSS). J Neural Transm (Vienna) (2015) 0.77
Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency Test. Alzheimers Res Ther (2014) 0.77
Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathol Commun (2015) 0.77
Mitochondrial abnormality associates with type-specific neuronal loss and cell morphology changes in the pedunculopontine nucleus in Parkinson disease. Am J Pathol (2013) 0.77
Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem. Brain Pathol (2014) 0.77
Freezing of Gait in Parkinson's Disease Is Associated with Reduced 6-[(18)F]Fluoro-l-m-tyrosine Uptake in the Locus Coeruleus. Parkinsons Dis (2016) 0.77
Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease. PLoS One (2016) 0.77
Which ante mortem clinical features predict progressive supranuclear palsy pathology? Mov Disord (2017) 0.77
Is there a need to redefine Parkinson's disease? J Neural Transm (Vienna) (2013) 0.76
Antioxidants inhibit neuronal toxicity in Parkinson's disease-linked LRRK2. Ann Clin Transl Neurol (2016) 0.76
The diagnostic value of minor salivary gland biopsy in clinically diagnosed patients with Parkinson's disease: comparison with DAT PET scans. Neurol Sci (2015) 0.75
Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinsons Dis (2016) 0.75
Systems biology of neurodegenerative diseases. Integr Biol (Camb) (2015) 0.75
Histone H3 acetylation in the postmortem Parkinson's disease primary motor cortex. Neurosci Lett (2016) 0.75
Splicing variants of porcine synphilin-1. Meta Gene (2015) 0.75
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron (2011) 20.15
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron (2011) 18.73
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
TREM2 variants in Alzheimer's disease. N Engl J Med (2012) 11.35
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA (2009) 8.40
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol (2006) 8.15
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology (2002) 7.73
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res (2004) 7.06
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Parkinson's disease. Lancet (2009) 6.60
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Toxic proteins in neurodegenerative disease. Science (2002) 5.82
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci (2007) 5.68
The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol (2010) 5.59
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Hum Mol Genet (2006) 5.50
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol (2008) 5.33
Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med (2010) 5.27
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol (2012) 5.18
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol (2006) 4.56
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Clinicopathological correlates in frontotemporal dementia. Ann Neurol (2004) 4.38
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
VPS35 mutations in Parkinson disease. Am J Hum Genet (2011) 4.16
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol (2007) 3.93
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Exome sequencing reveals de novo WDR45 mutations causing a phenotypically distinct, X-linked dominant form of NBIA. Am J Hum Genet (2012) 3.80
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol (2013) 3.70
Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol (2011) 3.69
Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet (2008) 3.66
Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol (2009) 3.62
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol (2010) 3.61
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology (2012) 3.46
Evolutionary toggling of the MAPT 17q21.31 inversion region. Nat Genet (2008) 3.42
Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol (2011) 3.36
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol (2011) 3.34
Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett (2005) 3.30
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet (2005) 3.29
Chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiol Aging (2011) 3.27
Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun (2011) 3.23
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain (2012) 3.08
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol (2006) 3.02
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol (2011) 3.01
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging (2003) 2.96
The pathological basis of semantic dementia. Brain (2005) 2.96
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol (2009) 2.87
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J Neurochem (2011) 2.82
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66